Aurora Cannabis Reports Record Q3 Revenue, Faces Share Decline

Aurora Cannabis reported an impressive financial performance for the third quarter of fiscal 2025, primarily driven by a 51% year-over-year surge in international medical cannabis sales, which contributed to a 37% increase in total net revenue to C$88.2 million. The company swung to a profit of C$31.2 million, largely bolstered by a C$42.4 million gain from the revaluation of biological assets, compared to a C$17.1 million loss in the prior-year period. The company's consumer cannabis segment, however, saw a 15% decline in revenue. Aurora also reported a significant rise in adjusted EBITDA to C$23.1 million and achieved a 74% gross margin in its medical cannabis division. Despite growth in revenue and profitability, Aurora Cannabis shares have declined by 13.4% year-to-date, underperforming the S&P 500. Looking forward, Aurora expects continued revenue growth in its cannabis business, supported by international expansion and strong margins.